Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
12:10pm, Friday, 30'th May 2025
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend investors remain on the sidelines at current levels.
Focus: Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
06:06am, Friday, 30'th May 2025
Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Admini
Gilead Sciences, Inc. (GILD) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
05:50pm, Thursday, 29'th May 2025
Gilead Sciences, Inc. (NASDAQ:GILD ) Bernstein Annual Strategic Decisions Conference May 29, 2025 2:30 PM ET Company Participants Dan O'Day - Chairman and Chief Executive Officer Conference Call Parti
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
10:06am, Thursday, 29'th May 2025
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences' Best Days May Be Ahead - Here's Why
10:32am, Monday, 26'th May 2025
Despite a sharp decline in sales of COVID-19 blockbuster Veklury, Gilead Sciences once again beat consensus revenue and EPS forecasts. The drugs whose performance impressed me greatly in Q1 2025 and w
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
10:21am, Monday, 26'th May 2025
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy). The stu
Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)
03:28pm, Wednesday, 21'st May 2025
Gilead Sciences, Inc. (NASDAQ:GILD ) RBC Capital Markets Global Healthcare Conference May 21, 2025 11:30 AM ET Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call Pa
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
10:41am, Wednesday, 21'st May 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
02:01pm, Tuesday, 20'th May 2025
Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space.
2 Dividend Stocks That are Holding Their Own in 2025
11:56am, Saturday, 17'th May 2025
Perhaps it's not all too surprising to witness the S&P 500 run into turbulence after two of the best years for stock gains in recent memory.
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
10:01am, Thursday, 15'th May 2025
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript
07:32pm, Tuesday, 13'th May 2025
Gilead Sciences, Inc. (NASDAQ:GILD ) BofA Securities Health Care Conference May 13, 2025 2:20 PM ET Company Participants Johanna Mercier – Chief Commercial Officer Conference Call Participants Tim A
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
12:36pm, Monday, 12'th May 2025
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
